ConductScience.org, home

Paper41576755

Advancements in targeted therapies for acute myeloid leukemia.

Connor MP and 3 others. Curr Opin Pharmacol, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Advancements in targeted therapies for acute myeloid leukemia. Papers, record 41576755. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41576755

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advancements in targeted therapies for acute myeloid leukemia.
PubMed
Journal
Curr Opin Pharmacol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Connor MPMatthew P
2Barsouk AAdam
3Elghawy OOmar
4Lai CCatherine

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
Molecular Targeted TherapyMajor topic
Antineoplastic AgentsMajor topic
Humans
Nucleophosmin
fms-Like Tyrosine Kinase 3
Animals
Isocitrate Dehydrogenase
Histone-Lysine N-Methyltransferase
Mutation
Signal Transduction

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
T32 CA009679NCI NIH HHSUnited StatesT32CA009679PubMed

Source NIH RePORTER

Download CSV of grants

References76

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112951584The role of FLT3 in haematopoietic malignancies.Nat Rev Cancer2003https://conductscience.org/library/papers/12951584PubMed
237116523
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet2023https://conductscience.org/library/papers/37116523PubMed
336151141Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.Leukemia2022https://conductscience.org/library/papers/36151141PubMed
438324741Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.J Clin Oncol2024https://conductscience.org/library/papers/38324741PubMed
532215183Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.Oncotarget2020https://conductscience.org/library/papers/32215183PubMed
630361262Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood2019https://conductscience.org/library/papers/30361262PubMed
732786187Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.N Engl J Med2020https://conductscience.org/library/papers/32786187PubMed
834349242Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.Oncogene2021https://conductscience.org/library/papers/34349242PubMed
920538800Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.Blood2010https://conductscience.org/library/papers/20538800PubMed
1026819452Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Clin Cancer Res2016https://conductscience.org/library/papers/26819452PubMed
1136150050Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.Blood Adv2022https://conductscience.org/library/papers/36150050PubMed
1231841594Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Blood2020https://conductscience.org/library/papers/31841594PubMed
1317957188MLL translocations, histone modifications and leukaemia stem-cell development.Nat Rev Cancer2007https://conductscience.org/library/papers/17957188PubMed
1435063965Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.Clin Cancer Res2022https://conductscience.org/library/papers/35063965PubMed
1535797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022https://conductscience.org/library/papers/35797463PubMed
1637871309A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Blood Adv2024https://conductscience.org/library/papers/37871309PubMed
1729090343Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).Ann Hematol2017https://conductscience.org/library/papers/29090343PubMed
1835732831The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.Leukemia2022https://conductscience.org/library/papers/35732831PubMed
1938471061Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.J Clin Oncol2024https://conductscience.org/library/papers/38471061PubMed
2015464450MLL: a histone methyltransferase disrupted in leukemia.Trends Mol Med2004https://conductscience.org/library/papers/15464450PubMed

See all 76 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42803869ANKRD28 interacts with DOCK180 to activate Rac1-STAT3-Myc signaling and sustain stemness of CD34+ leukemia stem cells in acute myeloid leukemia.Mol Cell Biochem2026https://conductscience.org/library/papers/42803869PubMed
42452347Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.J Clin Med2026https://conductscience.org/library/papers/42452347PubMed
42188361Evolving Management Approaches Toward Personalized Therapy in Acute Myeloid Leukemia: A Narrative Review.J Pers Med2026https://conductscience.org/library/papers/42188361PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
IDH13417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene
IDH23418PubTator's text mininghttps://conductscience.org/library/genes/3418NCBI Gene
KMT2A4297PubTator's text mininghttps://conductscience.org/library/genes/4297NCBI Gene
NPM14869PubTator's text mininghttps://conductscience.org/library/genes/4869NCBI Gene
RET5979PubTator's text mininghttps://conductscience.org/library/genes/5979NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41576755

GET https://conductscience.org/api/papers/v1/41576755/references?page=2